There was less percentage of CD133-positive and CD44-positive cancer cells in the Ad-Bmi-1i-treated xenograft tissues than in control group (Figure 4D), suggesting a potential inhibitory or killing role of Ad-Bmi-1i for gastric CSCs. This evidence concerns the gene CD44 and cancer.